Relationship between severity of hyperemesis gravidarum and fetal DNA concentration in maternal plasma.

Proc Natl Acad Sci U S A 1998;95:9465–70. 18. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J, et al. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 2001;22:665–71. 19. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2:25–31. 20. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225–35. 21. Bazrafshani MR, Ollier WE, Hajeer AH. A novel PCR-RFLP assay for the detection of the single nucleotide polymorphism at position 1082 in the human IL-10 gene promoter. Eur J Immunogenet 2000;27:119–20. 22. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, et al. Tumor necrosis factor promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001;97: 3707–12. 23. Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, et al. Gender-specific association between 1082 IL-10 promoter polymorphism and longevity. Genes Immun 2002;3:30–3. 24. Uboldi de Capei M, Dametto E, Fasano ME, Rendine S, Curtoni ES. Genotyping for cytokine polymorphisms: allele frequencies in the Italian population. Eur J Immunogenet 2003;30:5–10. 25. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, et al. Genetic variation in the tumor necrosis factorpromoter region and in the stress protein hsp70–2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001;91:672–8. 26. Park KS, Mok JW, Ko HE, Tokunaga K, Lee MH. Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur J Immunogenet 2002;29:7–10.